Workshop on local hyperthermia in patients with rectal cancer in Krasnodar

Insulin-like growth factors (IGF) 1 and 2 and IGF binding proteins (IGFBP) 1 and 3 levels were measured by ELISA techniques in blood serum of 74 primary colorectal cancer (СRC) patients and 30 control practically healthy persons. Significant increase of IGF-1 level and decrease of IGFBP-3 level were demonstrated in patients’ serum as compared to control group. Sensitivity of IGF-1 as a prospective diagnostic СRС marker comprised 80 % with 75 % specificity using 140 ng/ml as cut-off level. Significant negative association was found be-tween both patients and donors’ age and serum IGF-1 levels, but in CRC patients it was much weaker than in control group. No associations were found between serum IGF 1 and 2 levels and main criteria of colorectal cancer progression.

This report summarizes existing data on differential diagnosis between primary and metastatic ovarian cancer in patients with colorectal cancer (CRC). The results obtained in N.N. Blokhin Russian Cancer Research Center on the management of this malignancy are also presented. The evidence in favour of the need of genetic counseling and monitoring of the patients with aggravated familial history for early diagnosis of synchronous and metachronous ovarian cancer in patients with CRC is produced. A number of clinical, laboratory and diagnostic methods in addition to immunohistology and molecular genetics should be used for differential diagnosis of primary and metastatic ovarian cancer in patients with CRC.

The paper presents an analysis of rectal cancer incidence in the Republic of Belarus over the 30-year time period, assessing earliness of the diagnosis and treatment outcomes. From 1980 through 2010, rectal cancer incidence in Belarus increased 2.4-fold (from 8.9 to 21.0 per 100 000 population). The proportion of rectal cancer patients undergoing radical surgery grew from 32.4 % in 1985 to 57.2 % in 2010. One-year mortality rates decreased and were 37.6 % in 1994 and 27.2 % in 2010. The share of rectal cancer patients followed up for 5 years and more after establishing the diagnosis was 34.5 % in 1990 and 51.7 % in 2010.

Quality of life is the second most important clinical outcome criteria for cancer patients after survival. Quality of life shows the completeness of social rehabilitations of patients, who underwent radical treatment. In present study quality of life of 41 rectal cancer patients, who underwent abdominoperineal resection (n = 22) or anterior resection (n = 19) was assessed using SF-36 questionnaire. All patients without permanent colostomy had better postoperative quality of life. The phycho-emotional state of patients with permanent colostomy progres-sively decreases. The present study is important for developing an individualized rehabilitation programme for female rectal cancer patients.

The aim of the research: explore the possibilities of modern visual differential diagnostics of early colon cancer and bening colon tumors.

Methods.Results of endoscopic examination of 174 patients with unclear endoscopic data were analyzed. These patients underwent complex diagnostics, which revealed 293 tumors. Following groups were distinguished (according to the results of morphological study of biomaterial and visual endoscopic evaluation): early colon cancer – 28, lobular hyperplasia of the mucous shell – 38, polyps (adenomas with dysplasia varying degrees) – 184, limited infiltrative cancer – 37, neuroendocrine tumors – 6.

Results.Visual and morphological data coincided in 89.3 % patients, sensitivity 93.9 %, specificity of 88.6 %, positive predictive value 90.4 %, negative predictive value 82.4 %, accuracy of 89.6 %.

Conclusions. Use of the complex endoscopic diagnostics allows to identify the neoplastic changes of the mucous membrane in the early stages of development, and make a high-precision biopsy.

Treatment of patients with metastatic colorectal cancer (mCRC)  is one of the priority questions in oncology. Despite the significant progress in chemotherapy treatment, development of target agents is the only way of further improvement of the results. Bevacizumab (Avastin) is the first biologic demonstrated it’s efficacy in 1st and 2nd therapy lines in mCRC patients and what’s more important – in continuation with first two serial chemotherapy lines.

Author presents his own experience of prolonged bevacizumab (Avastin) therapy in several serial therapy lines in mCRC patient.